Literature DB >> 6507105

Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters.

B S Niklasson, G F Meadors, C J Peters.   

Abstract

The protection by active and passive immunization of Golden Syrian hamsters challenged with Rift Valley Fever (RVF) virus intraperitoneally was studied. Six groups of 10 hamsters were inoculated with different amounts of immune serum while five groups were actively immunized with different doses of a formalin-inactivated RVF vaccine. One day after passive and three weeks after active immunization all hamsters were challenged with 5000 plaque-forming units of RVF virus. Plaque reduction neutralization tests (PRNT) were performed with serum samples collected immediately before challenge. A PRNT titer of 10-20 or more was required for full protection against the RVF challenge in both actively and passively immunized hamsters. Actively immunized hamsters and control animals that succumbed to the infection died within the first 4 days after virus challenge, whereas some passively immunized hamsters died as late as 11 days post virus challenge. Animals that died early had developed massive liver necrosis, whereas late death was caused by encephalitis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6507105     DOI: 10.1111/j.1699-0463.1984.tb00074.x

Source DB:  PubMed          Journal:  Acta Pathol Microbiol Immunol Scand C        ISSN: 0108-0202


  29 in total

1.  In vitro and in vivo efficacy of a Rift Valley fever virus vaccine based on pseudovirus.

Authors:  Jian Ma; Ruifeng Chen; Weijin Huang; Jianhui Nie; Qiang Liu; Youchun Wang; Xiaoming Yang
Journal:  Hum Vaccin Immunother       Date:  2019-06-20       Impact factor: 3.452

Review 2.  Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies.

Authors:  Brian B Gowen; Brady T Hickerson
Journal:  J Microbiol       Date:  2017-02-28       Impact factor: 3.422

3.  Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice.

Authors:  James F Papin; Paulo H Verardi; Leslie A Jones; Francisco Monge-Navarro; Aaron C Brault; Michael R Holbrook; Melissa N Worthy; Alexander N Freiberg; Tilahun D Yilma
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-23       Impact factor: 11.205

4.  Potent neutralization of Rift Valley fever virus by human monoclonal antibodies through fusion inhibition.

Authors:  Nathaniel S Chapman; Haiyan Zhao; Nurgun Kose; Jonna B Westover; Birte Kalveram; Robin Bombardi; Jessica Rodriguez; Rachel Sutton; Joseph Genualdi; A Desiree LaBeaud; Francis M Mutuku; Phillip R Pittman; Alexander N Freiberg; Brian B Gowen; Daved H Fremont; James E Crowe
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

5.  Experimental Rift Valley fever in rhesus macaques.

Authors:  C J Peters; D Jones; R Trotter; J Donaldson; J White; E Stephen; T W Slone
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

6.  Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment.

Authors:  Dionna Scharton; Kevin W Bailey; Zachary Vest; Jonna B Westover; Yohichi Kumaki; Arnaud Van Wettere; Yousuke Furuta; Brian B Gowen
Journal:  Antiviral Res       Date:  2014-01-31       Impact factor: 5.970

Review 7.  Rift valley fever vaccines.

Authors:  Tetsuro Ikegami; Shinji Makino
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

8.  Rapid accumulation of virulent rift valley Fever virus in mice from an attenuated virus carrying a single nucleotide substitution in the m RNA.

Authors:  John C Morrill; Tetsuro Ikegami; Naoko Yoshikawa-Iwata; Nandadeva Lokugamage; Sungyong Won; Kaori Terasaki; Aya Zamoto-Niikura; C J Peters; Shinji Makino
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

9.  Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep.

Authors:  John C Morrill; Richard C Laughlin; Nandadeva Lokugamage; Roberta Pugh; Elena Sbrana; William J Weise; L Garry Adams; Shinji Makino; C J Peters
Journal:  Vaccine       Date:  2012-11-12       Impact factor: 3.641

10.  A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

Authors:  Robert B Mandell; Ramesh Koukuntla; Laura J K Mogler; Andrea K Carzoli; Alexander N Freiberg; Michael R Holbrook; Brian K Martin; William R Staplin; Nicholas N Vahanian; Charles J Link; Ramon Flick
Journal:  Virology       Date:  2009-11-24       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.